UPDATED: State Joins "Pause" in Johnson & Johnson Vaccine
The state is “pausing” use of the Johnson & Johnson/Janssen COVID-19 vaccine after 6 blood clotting cases have popped up in nearly 7 million doses administered.
Joining a federal call to “pause” injections of the Johnson & Johnson/Janssen vaccine, state officials announced Tuesday they were pausing distribution, too.
In accordance with recommendations from the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA), the Illinois Department of Public Health (IDPH) will pause the use of the Johnson & Johnson (J&J) COVID-19 vaccine out of an abundance of caution. The CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type blood clot in individuals after receiving the J&J vaccine.
IDPH has notified all Illinois COVID-19 providers throughout the state to discontinue use of the J&J vaccine at this time. In order to keep appointments, IDPH is strongly advising providers to use Pfizer-BioNTech and Moderna vaccines.
Moderna and Pfizer make up the vast majority of doses on hand in the State of Illinois. This week, the state’s allocation of J&J was 17,000 doses. For the week of April 18, 2021, the expected allocation for the State is 483,720 total doses. Of that total allocation, 5,800 doses were expected to be J&J.
Per the federal health authorities, people who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Patients with other clinical questions should contact their health care provider.
IDPH will continue to update the public as additional information becomes available.
Due to a production problem, there was expected to be dramatically fewer Johnson & Johnson shots available in Illinois this week anyway. In a statement this morning, Johnson & Johnson confirmed the blood clotting impacted six of 6.8 million people vaccinated with the J&J product in the United States.
UPDATE (3:33 P.M.):
Via IDPH:
“Public health officials made a commitment that any safety signals that came up concerning COVID-19 vaccines would be fully addressed in a transparent manner, which is what is occurring right now with the J&J vaccine,” said IDPH Director Dr. Ngozi Ezike. “The blood clot cases appear to be extremely rare and there are no reported cases associated with either the Pfizer-BioNTech or the Moderna vaccines. IDPH is taking immediate action to ensure as little disruption to Illinois residents as possible during this pause, and I strongly encourage people to continue to get vaccinated. Millions upon millions of people have already been safely vaccinated and it will take millions more before we can put this pandemic behind us.”
Upon learning of the recommendation, IDPH took the following actions to ensure COVID-19 vaccine providers and health care workers in Illinois were aware of the pause and received the support they needed to adjust their planning:
• Immediately sent notification about the pause to COVID-19 providers, local health departments, and health care providers via the State of Illinois Rapid Electronic Notification system, which included follow-up calls, text, and emails.
• Directly emailed and called all local health departments through IDPH Emergency Response Coordinators, to assess impact and work to mitigate using Pfizer-BioNTech and Moderna vaccines.
• Connected with all mass vaccination sites, Illinois National Guard vaccination missions, and one-day J&J clinics scheduled in EMTrack to develop alternate plans where necessary and ensure the least amount of disruption possible on individuals with appointments.
• Sent notification to hospitals, emergency departments, physicians, and other health care providers about treatment for this specific type of blood clot
The pause on the J&J vaccine will not have a large impact on state vaccination efforts as the Moderna and Pfizer-BioNTech vaccines make up the vast majority of doses on hand in the State of Illinois. No state-supported mass vaccination sites will be closed and no rapid response team clinics, faith-based or equity clinics, or rural clinics have been cancelled at this time. They will all move forward with a different type of vaccine.
The total allocation of J&J vaccine to Illinois, including Chicago, is 760,300, of which 290,615 doses have been administered. This week, the state’s allocation of J&J was 17,000 doses. For the week of April 18, 2021, the expected allocation for the State is 483,720 total doses. Of that total allocation, 5,800 doses were expected to be J&J.
In an effort to vaccinate as many people as possible across Illinois, the State is allocating 50,000 first doses of Moderna and Pfizer-BioNTech vaccine to the City of Chicago over the next seven days to help meet demand. The State will also be allocating 50,000 doses to Chicago when second doses come due to be administered.
—
